Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension (Q37656327)

21 August 2017

1 reference

title

Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension (English)

1 reference

21 August 2017

arterial hypertension

0 references

1 reference

Mantej K Chhina

1

1 reference

21 August 2017

Weir Nargues

series ordinal

2

1 reference

21 August 2017

Geraldine M Grant

series ordinal

3

1 reference

21 August 2017

Steven D Nathan

series ordinal

4

1 reference

21 August 2017

language of work or name

1 reference

1 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

6

1 reference

21 August 2017

1

1 reference

21 August 2017

19-35

1 reference

Clinical classification of pulmonary hypertension.

21 August 2017

1 reference

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

Pulmonary hypertension associated with left-sided heart disease

21 January 2018

1 reference

Diagnosis and management of pulmonary hypertension over the past 100 years

21 January 2018

1 reference

Pulmonary Arterial Hypertension

21 January 2018

1 reference

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

21 January 2018

1 reference

Evaluation of pulmonary arterial hypertension.

21 January 2018

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

PDGF signaling in pulmonary arterial hypertension

21 January 2018

1 reference

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

An epidemiological study of pulmonary arterial hypertension.

21 January 2018

1 reference

Leads for the treatment of pulmonary hypertension

21 January 2018

1 reference

Expert opinion on available options treating pulmonary arterial hypertension

21 January 2018

1 reference

Primary pulmonary hypertension. A national prospective study

21 January 2018

1 reference

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.

21 January 2018

1 reference

Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension

21 January 2018

1 reference

The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).

21 January 2018

1 reference

Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.

21 January 2018

1 reference

HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study

21 January 2018

1 reference

Primary pulmonary hypertension in HIV infection

21 January 2018

1 reference

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence

21 January 2018

1 reference

Sildenafil: a review of its use in pulmonary arterial hypertension

21 January 2018

1 reference

Role of endothelin-1 in lung disease

21 January 2018

1 reference

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications

21 January 2018

1 reference

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

21 January 2018

1 reference

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

21 January 2018

1 reference

Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

21 January 2018

1 reference

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol

21 January 2018

1 reference

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

Evaluation and management of the patient with pulmonary arterial hypertension

21 January 2018

1 reference

Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review

21 January 2018

1 reference

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

Interventional and surgical modalities of treatment in pulmonary hypertension

21 January 2018

1 reference

A USA-based registry for pulmonary arterial hypertension: 1982-2006.

21 January 2018

1 reference

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

Pathologic assessment of vasculopathies in pulmonary hypertension

21 January 2018

1 reference

Cellular and molecular basis of pulmonary arterial hypertension

21 January 2018

1 reference

Development and pathology of pulmonary hypertension.

21 January 2018

1 reference

Genetics and genomics of pulmonary arterial hypertension

21 January 2018

1 reference

Role of platelet-derived growth factors in physiology and medicine

21 January 2018

1 reference

Role of PDGF in fibrotic diseases and systemic sclerosis

21 January 2018

1 reference

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family

21 January 2018

1 reference

Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

PDGF and microvessel wall remodeling in adult lung: imaging PDGF-Rbeta and PDGF-BB molecules in progenitor smooth muscle cells developing in pulmonary hypertension.

21 January 2018

1 reference

PDGF and microvessel wall remodeling in adult rat lung: imaging PDGF-AA and PDGF-Ralpha molecules in progenitor smooth muscle cells developing in experimental pulmonary hypertension.

21 January 2018

1 reference

Alterations in Ca2+ cycling by lysoplasmenylcholine in adult rabbit ventricular myocytes

21 January 2018

1 reference

Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling

21 January 2018

1 reference

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

21 January 2018

1 reference

Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by mo

21 January 2018

1 reference

Specific targeted therapy of chronic myelogenous leukemia with imatinib

21 January 2018

1 reference

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

21 January 2018

1 reference

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia

21 January 2018

1 reference

Treatment of chronic myeloid leukemia with imatinib mesylate

21 January 2018

1 reference

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

21 January 2018

1 reference

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

21 January 2018

1 reference

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

21 January 2018

1 reference

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

21 January 2018

1 reference

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

21 January 2018

1 reference

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

Metabolism and disposition of imatinib mesylate in healthy volunteers

21 January 2018

1 reference

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

21 January 2018

1 reference

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Long term imatinib treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

Possible role of imatinib in clinical pulmonary veno-occlusive disease

21 January 2018

1 reference

Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?

21 January 2018

1 reference

Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension

21 January 2018

1 reference

Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.

21 January 2018

1 reference

Future perspectives for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss

21 January 2018

1 reference

21 January 2018

1 reference

Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration

21 January 2018

1 reference

Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

21 January 2018

1 reference

Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FCA.09.54

1 reference

21 August 2017

1 reference